104 related articles for article (PubMed ID: 2585396)
1. Irreversible renal failure after intraperitoneal cisplatin administration. A case report.
Gouge SF; Tietjen DP; Moore J
J Reprod Med; 1989 Nov; 34(11):931-3. PubMed ID: 2585396
[TBL] [Abstract][Full Text] [Related]
2. [Pharmacokinetic study of intraperitoneal chemotherapy with high-dose cisplatin for advanced ovarian cancer].
Deng C; Huang R; Lian L
Zhonghua Fu Chan Ke Za Zhi; 1996 Mar; 31(3):159-62. PubMed ID: 8758790
[TBL] [Abstract][Full Text] [Related]
3. Severe neurotoxicity, ototoxicity and nephrotoxicity following high-dose cisplatin and amifostine.
Sastry J; Kellie SJ
Pediatr Hematol Oncol; 2005; 22(5):441-5. PubMed ID: 16020136
[TBL] [Abstract][Full Text] [Related]
4. A phase II study of intraperitoneal cisplatin and thiotepa in residual ovarian carcinoma: a Gynecologic Oncology Group study.
Feun LG; Blessing JA; Major FJ; DiSaia PJ; Alvarez RD; Berek JS
Gynecol Oncol; 1998 Dec; 71(3):410-5. PubMed ID: 9887240
[TBL] [Abstract][Full Text] [Related]
5. Consolidation intraperitoneal chemotherapy in epithelial ovarian cancer patients following negative second-look laparotomy.
Tarraza HM; Boyce CR; Smith WG; Jones MA
Gynecol Oncol; 1993 Sep; 50(3):287-90. PubMed ID: 8406188
[TBL] [Abstract][Full Text] [Related]
6. [Renal toxicity of intraperitoneal cisplatin: a case report].
Thomas C; Quinio P
J Gynecol Obstet Biol Reprod (Paris); 1992; 21(4):445-6. PubMed ID: 1624733
[TBL] [Abstract][Full Text] [Related]
7. Intraperitoneal cisplatin chemotherapy in the management of ovarian carcinoma.
Markman M
Semin Oncol; 1989 Aug; 16(4 Suppl 6):79-82. PubMed ID: 2669140
[TBL] [Abstract][Full Text] [Related]
8. High-intensity intravenous cyclophosphamide and cisplatin, interim surgical debulking, and intraperitoneal cisplatin in advanced ovarian carcinoma: a pilot trial with ten-year follow-up.
Shapiro F; Schneider J; Markman M; Reichman BS; Venkatraman E; Barakat R; Almadrones L; Spriggs D
Gynecol Oncol; 1997 Oct; 67(1):39-45. PubMed ID: 9345354
[TBL] [Abstract][Full Text] [Related]
9. Phase II trial of combination intraperitoneal cisplatin and 5-fluorouracil in previously treated patients with advanced ovarian cancer: long-term follow-up.
Morgan RJ; Braly P; Leong L; Shibata S; Margolin K; Somlo G; McNamara M; Longmate J; Schinke S; Raschko J; Nagasawa S; Kogut N; Najera L; Johnson D; Doroshow JH
Gynecol Oncol; 2000 Jun; 77(3):433-8. PubMed ID: 10831355
[TBL] [Abstract][Full Text] [Related]
10. Intraperitoneal high-dose cisplatin and etoposide with systemic thiosulfate protection in second-line treatment of advanced ovarian cancer.
Malmström H; Rasmussen S; Simonsen E
Gynecol Oncol; 1993 May; 49(2):166-71. PubMed ID: 8504983
[TBL] [Abstract][Full Text] [Related]
11. Intraperitoneal cisplatin and intravenous paclitaxel in the treatment of epithelial ovarian cancer patients with a positive second look.
Makhija S; Sabbatini P; Aghajanian C; Venkatraman E; Spriggs DR; Barakat R
Gynecol Oncol; 2000 Oct; 79(1):28-32. PubMed ID: 11006026
[TBL] [Abstract][Full Text] [Related]
12. [Definitive end-stage chronic kidney failure after cisplatin treatment].
Brillet G; Deray G; Lucsko M; Faucher C; Aubert P; Rottembourg J; Jacobs C
Nephrologie; 1993; 14(5):227-9. PubMed ID: 8159252
[TBL] [Abstract][Full Text] [Related]
13. Feasibility of using intraperitoneal epinephrine and cisplatin in patients with advanced peritoneal carcinomatosis.
Molucon-Chabrot C; Isambert N; Benoit L; Zanetta S; Fraisse J; Guilland JC; Royer B; Monin-Baroille P; Flesch M; Fargeot P; Coudert B; Mayer F; Fumoleau P; Chauffert B
Anticancer Drugs; 2006 Nov; 17(10):1211-7. PubMed ID: 17075321
[TBL] [Abstract][Full Text] [Related]
14. Improvement in intraperitoneal intraoperative cisplatin exposure based on pharmacokinetic analysis in patients with ovarian cancer.
Royer B; Delroeux D; Guardiola E; Combe M; Hoizey G; Montange D; Kantelip JP; Chauffert B; Heyd B; Pivot X
Cancer Chemother Pharmacol; 2008 Mar; 61(3):415-21. PubMed ID: 17503047
[TBL] [Abstract][Full Text] [Related]
15. Randomized trial of initial therapy with melphalan versus cisplatin-based combination chemotherapy in patients with advanced ovarian carcinoma: initial and long term results--Eastern Cooperative Oncology Group Study E2878.
Wadler S; Yeap B; Vogl S; Carbone P
Cancer; 1996 Feb; 77(4):733-42. PubMed ID: 8616766
[TBL] [Abstract][Full Text] [Related]
16. Protective effect of intra-peritoneal epinephrine on postoperative renal function after cisplatin-based intra-peritoneal intra-operative chemotherapy.
Pili-Floury S; Royer B; Bartholin F; Crumiere N; Combe M; Chalopin JM; Pivot X; Heyd B; Chauffert B; Samain E
Eur J Obstet Gynecol Reprod Biol; 2011 Jun; 156(2):199-203. PubMed ID: 21306815
[TBL] [Abstract][Full Text] [Related]
17. [Intraperitoneal cisplatin chemotherapy for ovarian cancer].
Hayashi H; Nishii H; Ueda K; Kunitou S; Wada S; Takanashi H; Kobayashi S; Yasuda M
Gan To Kagaku Ryoho; 2001 Dec; 28(13):2043-8. PubMed ID: 11791382
[TBL] [Abstract][Full Text] [Related]
18. [Renal toxicity by intraperitoneal administration of CDDP].
Chen JT; Yamashiro T; Shimizu Y; Kuo TC; Nakayama K; Teshima H; Hirai Y; Hamada T; Fujimoto I; Yamauchi K
Nihon Sanka Fujinka Gakkai Zasshi; 1988 May; 40(5):534-40. PubMed ID: 3385274
[TBL] [Abstract][Full Text] [Related]
19. Cisplatin nephrotoxicity: symptomatic hypomagnesemia and renal failure.
Gomez Campdera FJ; Gonzalez P; Carrillo A; Estelles MC; Rengel M
Int J Pediatr Nephrol; 1986; 7(3):151-2. PubMed ID: 3804580
[TBL] [Abstract][Full Text] [Related]
20. The incidence of cisplatin nephrotoxicity post hyperthermic intraperitoneal chemotherapy (HIPEC) and cytoreductive surgery.
Hakeam HA; Breakiet M; Azzam A; Nadeem A; Amin T
Ren Fail; 2014 Nov; 36(10):1486-91. PubMed ID: 25155314
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
